Women are more likely to swap their prescription medication for medical cannabis, a study has found.
Researchers in the US have found that women are more likely to use medical cannabis than men – and to reduce using prescription drugs as a result. Treating fibromyalgia is among the most common reasons for using medical cannabis cited in the report.
The study, which was carried out by a team at DePaul University in Chicago, examined the behaviours of medical cannabis patients with a range of chronic health conditions in Illinois.
In the state, patients do not need a prescription, but must have one of a number of conditions to qualify for a medical cannabis card.
Researchers concluded that women ‘appear to be more likely than men’ to use medical cannabis for a range of symptoms, including pain, anxiety, inflammation and nausea.
Although previous population studies have shown that men are more likely to use cannabis recreationally, women were found to increase their consumption since qualifying for medical cannabis and as a result have ’reduced or completely discontinued’ any prescribed medications they were taking.
The study came about following interviews with medical cannabis patients about how they use cannabis, either as a complementary or alternative treatment or to reduce prescription medication altogether.
“This was a correlational, cross-sectional study, in which we were looking at potential correlates of the discontinuation of prescription medication and female gender appeared to be one of them,” lead author and associate professor in health sciences at DePaul University Dr Douglas Bruce told Cannabis Health.
“We didn’t go into the study thinking that men and women were using cannabis differently, but women seem to be adopting medical cannabis in a way that parallels with how women are more likely to access alternative and complementary treatments, such as yoga, guided meditation or acupuncture.“
The women in the study also reported ‘marginally lower levels’ of support from their primary care provider, and ‘significantly less support’ from specialist physicians than the men, which researchers believe could point to why women are more likely to look for other options.
“The study suggests interesting patterns and maps onto findings of other studies which weren’t looking at medical cannabis specifically, but alternative complementary therapy trends,” continued Dr Bruce.
“I’ve worked in public health for many years and there are feminist theories which would argue that men are less likely to seek out healthcare than women, and that women may be more likely to seek out alternatives due to less satisfaction with the medical care they receive.”
He added: “There are gendered patterns in terms of medical care utilisation and diagnoses that feed into women seeking out alternatives and being less bound by conventions regarding going to the doctor.”
The majority of women in the study reported fibromyalgia [a condition which is said to affect around seven times as many women as men] as their chief qualifying condition for medical cannabis, while in men the most common conditions were PTSD, spinal cord injury and cancer.
“We controlled for fibromyalgia, given that around 80 percent of those with fibromyalgia sufferers in the study were women, but the parameters of the final model remained the same, with the key differences being gender, the amount of support from a provider and whether the patient was treating multiple symptoms,” explained Dr Bruce.
A paper Dr Bruce and his team published earlier this year found that those with multiple symptoms were more likely to report experiencing some benefit from medical cannabis.
“Medical cannabis seems to infer the successful mitigation of a range of symptoms that may reinforce one another,” he said of the findings.
“Those who were treating multiple symptoms were more likely to rate cannabis as efficacious, which suggests some benefit in people using cannabis products instead of different classes of prescription medications to treat their individual symptoms, which is typically how they are prescribed.”
The report concludes that more ‘patient-centered studies’ on medical cannabis are needed to ‘understand differences in dosing, outcomes, beliefs, attitudes, formulations, pharmacology, and metabolism between men and women’.
“There’s a whole pharmacological universe that may be gendered, particularly in terms of how men and women metabolise these products,” added Dr Bruce.
“Medical cannabis is a real patient-driven phenomenon and one of my aims in conducting this kind of patient-centred research is that physicians will start to learn from their patients.
“More open communication within the medical practice will benefit both the patients and the provider.”
Molson Coors brings first CBD beverage to US
Mega brewer Molson Coors has announced its new line of non-alcoholic, sparkling CBD beverages in the US and it expands ‘beyond the beer aisle’.
The joint venture between brewing giant Molson Coors Beverage Company and Canadian cannabis firm HEXO Corp has announced its first US CBD drink will hit the market this month.
Launched by Truss CBD, Veryvell is a new line of non-alcoholic, sparkling CBD beverages, available exclusively for consumers in Colorado.
It marks the company’s first entry into the American CBD market since its inception and is another example of Molson Coors’ moves to cultivate the company’s beverage offerings.
“Last year we redefined ourselves as Molson Coors Beverage Company and in doing so, laid out a clear vision of leveraging the competitive strengths of our storied foundation in beer to grow in new spaces beyond the beer aisle,” said Pete Marino, president of the emerging growth division for Molson Coors.
“Truss’ entry into the CBD market in Colorado and the launch of Veryvell, a brand we believe will resonate well with Colorado consumers, is another example of Molson Coors’ expansion into new beverage categories.”
Veryvell has been described as having a crisp taste, containing zero calories, zero sugar and comes in three distinct varieties, each infused with 20mg of hemp-derived, non-psychoactive CBD and adaptogens.
These include, Focus, a combination of grapefruit and tarragon, Mind & Body, a blend of strawberry and hibiscus and Unwind, a mix of blueberry and lavender with ashwagandha and L-Theanine.
Jane Armstrong Hockman, Truss CBD USA general manager commented: “Whether you’ve dabbled in CBD before or are curious to try something new, Veryvell invites a moment of self-care to your day through a refreshing and balanced mix of hemp extracts and natural flavours.
“Each beverage in the product line offers a unique blend of CBD and adaptogens, giving consumers the freedom to pick the combination that best meets them in the moment. We are thrilled to bring our beverage expertise and commitment to quality to this emerging wellness category.
Veryvell is produced and distributed exclusively within Colorado, following the state’s established regulatory framework for hemp-derived CBD in food and beverages.
The diversification of the Molson Coors portfolio also includes an exclusive agreement with The Coca Cola Company to manufacture, market, and distribute Topo Chico Hard Seltzer in the US as well as an expanding roster of non-alcoholic innovations.
This includes a new energy drink being launched by a multi-faceted team of fitness, health and beverage industry change makers including Dwayne “The Rock” Johnson.
Follow @liveveryvell on Facebook and Instagram or visit www.trusscbdusa.com/
CBD and anxiety: What the research says
With more and more people reporting the use of CBD to ease stress and anxiety in these uncertain times, is the research there to back it up?
With a global pandemic raging, and many of us cut off from our friends and loved ones, it is no surprise that levels of anxiety and stress are at a high right now.
With many of our traditional stress-relieving activities – going to the gym, seeing a friend, travelling – out of bounds, and concern mounting about a rise in alcohol use, people are increasingly looking for alternative ways to relax.
A number of recent developments have once again highlighted the value of CBD in treating anxiety – so much so that a Canadian firm is developing a prescription drug based on the compound.
EmpowerPharm Inc is currently developing a unique prescription drug containing synthetic CBD as the active pharmaceutical ingredient to treat anxiety.
Pending the results of clinical research, it is thought the drug may help the thousands of Canadians who suffer from anxiety, as the firm has identified a growing need for innovative therapies as alternative treatments to avoid the addictive prescription products currently prescribed.
Meanwhile, CBD is also growing in popularity among those using it on a more recreational basis; almost half of UK users have increased their consumption since the pandemic.
A recent poll has found that more than a third (33 per cent) of Britons have tried CBD products, while 42 per cent have increased their usage since the outbreak of Covid-19, with anxiety the most common reason for using them.
While CBD has long had a reputation for promoting relaxation, research is still ongoing.
A landmark study in the US – billed as the first of its kind – was launched in October last year to investigate CBD’s use as a formal anxiety treatment.
The Cannabinoid Anxiety Relief Education Study is targeting millions of CBD and cannabis users across the US to assess the potential role of cannabinoids in reducing anxiety and other co-morbid conditions, such as insomnia and depression.
Such large-scale research is especially relevant given high Covid-19-caused anxiety levels, with many state and local governments deeming cannabis businesses “essential” and thus able to remain open during restrictions.
However, there are concerns that, while CBD can certainly help to relieve anxiety in the short-term, it is nothing more than a ‘sticking plaster’ solution.
Studies conducted by a team at Washington State University, led by phycology professor Dr Carrie Cuttler, analysed data from hundreds of people who recorded their symptoms before and after cannabis consumption.
Findings showed that in people who self-reported as having PTSD, cannabis reduced the severity of intrusive thoughts by about 62 per cent; for irritability it was 67 per cent and anxiety by 57 per cent.
However, researchers also found that there is no indication that cannabis reduced symptoms in the long-term.
Dr Cuttler cautioned: “We see a general theme that immediately after using cannabis most of the symptoms of these conditions are reduced by just over 50 percent.
“The bottom line is that it can work as an effective mask of the symptoms temporarily but it’s not benefiting the individuals in the long term.”
Such research points to the fact that, whole CBD may not be a solution for long-term anxiety, it is a useful took for treating shorter spells of stress – such as those caused by the pandemic.
US cannabis veteran launches pure CBD range
Cannabis entrepeneur, Jason Navarrete, who has almost two decades of experience in the sector, has launched a range of highly bio-available CBD products.
After selling his multi-million cannabis empire, US businessman, Navarrete has announced the launch of his new CBD range.
Navarrete is well-known in the industry having built a huge cannabis conglomerate in Southern California over the last 18 years.
Worth more than $250 million, the 120,000 square feet facility, across three industrial warehouses, focuses on high-tech hydroponic indoor cultivation, manufacturing, distribution and retail.
He sold the empire in early 2020 and transitioned from cultivating cannabis to creating what he claims are the purest CBD products on the market with his newest venture, Pure Craft CBD.
Pure Craft products are 90 percent bio-available, where most of those on the market are no more than 18 percent.
The company says being highly bio-available means Pure Craft products enter the body at a much quicker rate and are more effective than other products because they are broken down into particles that the body can absorb immediately.
Navarrete worked closely with MIT researchers to cultivate the cannabis and develop the line that includes nano-optimised broad spectrum water-soluble CBD tinctures along with soft gels, vegan gummies, CBD pet tincture, CBD broad spectrum oil and CBD with melatonin to promote sleep.
The team is also working on a full line of nano water-soluble tinctures from 600 – 3,000mg, in peppermint, tropical, strawberry mojito, orange cream, blueberry and vanilla flavours.
Navarrete believes the CBD industry is lacking the experience of cultivation experts, such as himself.
“When it comes to CBD, a lot of companies online are looking at the money aspect of an emerging industry,” he says.
“I’ve been cultivating cannabis for eighteen years. This industry is sorely lacking cultivation experts. That’s why scientists have reached out to work with me in their research.”
Navarrete explains a key factor in how he oversees his “seed to sale” process.
“We only partner with farmers that understand the importance of genetics and science in regard to cultivating premium hemp biomass.
“Our products are made following the strictest guidelines and quality control measures, allowing us to call them pharmaceutical grade.”
He is also sharing that wisdom with young entrepreneurs as an adjunct professor at the Center for Entrepreneurship at California State University, Fullerton, where he teaches young entrepreneurs about business basics.
“I’ve learned these lessons the hard way,” he explains.
“Teaching these young students the insights, skills and tricks of the trade makes me feel as if I am contributing to their entrepreneurial dreams to help them become more successful faster. The way I look at it, everything is a game and how much money you make is how you keep score.”
Pure Craft CBD offers 16 different cannabis products, which all come with third-party lab COAs (Certificates of Analysis) so consumers know exactly what’s in them and how they were tested every time.
News6 months ago
NHS lines up cannabis medicine manufacturing
News2 months ago
Community extends support to cannabis icon Rick Simpson
Case Studies10 months ago
CBD oil and fibromyalgia – a case study
Insight3 months ago
I’ve gone from a wheelchair to walking thanks to cannabis
Feature7 months ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
News4 months ago
“I’m not a bad person” – chronically ill woman convicted of growing medical cannabis
News4 months ago
Cancer survivor claims cannabis oil helped her beat brain tumour
News4 months ago
Mum of three-year-old with ‘one in a million’ condition fights for medical cannabis funding